Human herpesvirus 6B immediate-early I protein contains functional HLA-A*02, HLA-A*03, and HLA-B*07 class I restricted CD8+ T-cell epitopes

Mathieu Iampietro, Guillaume Morissette, Annie Gravel, Isabelle Dubuc, Matthieu Rousseau, Aisha Hasan, Richard J. O'Reilly, Louis Flamand

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Human herpesvirus 6B (HHV-6B) is a ubiquitous pathogen with frequent reactivation observed in immunocompromised patients such as BMtransplant (BMT) recipients. Adoptive immunotherapy is a promising therapeutic avenue for the treatment of opportunistic infections, including herpesviruses. While T-cell immunotherapy can successfully control CMV and EBV reactivations in BMT recipients, such therapy is not available for HHV-6 infections, in part due to a lack of identified protective CD8+ T-cell epitopes. Our goal was to identify CD8+ T-cell viral epitopes derived from the HHV-6B immediate-early protein I and presented by common human leukocyte Ag (HLA) class I alleles including HLA-A*02, HLA-A*03, and HLA-B*07. These epitopes were functionally tested for their ability to induce CD8+ T-cell expansion and kill HHV-6-infected autologous cells. Cross-reactivity of specific HHV-6B-expanded T cells against HHV-6A-infected cells was also confirmed for a conserved epitope presented by HLA-A*02 molecule. Our findings will help push forward the field of adoptive immunotherapy for the treatment and/or the prevention of HHV-6 reactivation in BMT recipients.

Original languageEnglish (US)
Pages (from-to)3573-3584
Number of pages12
JournalEuropean Journal of Immunology
Volume44
Issue number12
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Immediate-Early Proteins
Human Herpesvirus 6
T-Lymphocyte Epitopes
Leukocytes
Adoptive Immunotherapy
T-Lymphocytes
Epitopes
Herpesviridae
Opportunistic Infections
Immunocompromised Host
Therapeutics
Human Herpesvirus 4
Immunotherapy
Alleles
Infection

Keywords

  • CD8 T cells
  • HHV-6
  • Immediate-early 1 protein
  • Immunotherapy
  • Infectious disease
  • Virology

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Medicine(all)

Cite this

Human herpesvirus 6B immediate-early I protein contains functional HLA-A*02, HLA-A*03, and HLA-B*07 class I restricted CD8+ T-cell epitopes. / Iampietro, Mathieu; Morissette, Guillaume; Gravel, Annie; Dubuc, Isabelle; Rousseau, Matthieu; Hasan, Aisha; O'Reilly, Richard J.; Flamand, Louis.

In: European Journal of Immunology, Vol. 44, No. 12, 2014, p. 3573-3584.

Research output: Contribution to journalArticle

Iampietro, M, Morissette, G, Gravel, A, Dubuc, I, Rousseau, M, Hasan, A, O'Reilly, RJ & Flamand, L 2014, 'Human herpesvirus 6B immediate-early I protein contains functional HLA-A*02, HLA-A*03, and HLA-B*07 class I restricted CD8+ T-cell epitopes', European Journal of Immunology, vol. 44, no. 12, pp. 3573-3584. https://doi.org/10.1002/eji.201444931
Iampietro, Mathieu ; Morissette, Guillaume ; Gravel, Annie ; Dubuc, Isabelle ; Rousseau, Matthieu ; Hasan, Aisha ; O'Reilly, Richard J. ; Flamand, Louis. / Human herpesvirus 6B immediate-early I protein contains functional HLA-A*02, HLA-A*03, and HLA-B*07 class I restricted CD8+ T-cell epitopes. In: European Journal of Immunology. 2014 ; Vol. 44, No. 12. pp. 3573-3584.
@article{0eac6faec36b4cca82a09bc5f68950ac,
title = "Human herpesvirus 6B immediate-early I protein contains functional HLA-A*02, HLA-A*03, and HLA-B*07 class I restricted CD8+ T-cell epitopes",
abstract = "Human herpesvirus 6B (HHV-6B) is a ubiquitous pathogen with frequent reactivation observed in immunocompromised patients such as BMtransplant (BMT) recipients. Adoptive immunotherapy is a promising therapeutic avenue for the treatment of opportunistic infections, including herpesviruses. While T-cell immunotherapy can successfully control CMV and EBV reactivations in BMT recipients, such therapy is not available for HHV-6 infections, in part due to a lack of identified protective CD8+ T-cell epitopes. Our goal was to identify CD8+ T-cell viral epitopes derived from the HHV-6B immediate-early protein I and presented by common human leukocyte Ag (HLA) class I alleles including HLA-A*02, HLA-A*03, and HLA-B*07. These epitopes were functionally tested for their ability to induce CD8+ T-cell expansion and kill HHV-6-infected autologous cells. Cross-reactivity of specific HHV-6B-expanded T cells against HHV-6A-infected cells was also confirmed for a conserved epitope presented by HLA-A*02 molecule. Our findings will help push forward the field of adoptive immunotherapy for the treatment and/or the prevention of HHV-6 reactivation in BMT recipients.",
keywords = "CD8 T cells, HHV-6, Immediate-early 1 protein, Immunotherapy, Infectious disease, Virology",
author = "Mathieu Iampietro and Guillaume Morissette and Annie Gravel and Isabelle Dubuc and Matthieu Rousseau and Aisha Hasan and O'Reilly, {Richard J.} and Louis Flamand",
year = "2014",
doi = "10.1002/eji.201444931",
language = "English (US)",
volume = "44",
pages = "3573--3584",
journal = "European Journal of Immunology",
issn = "0014-2980",
publisher = "Wiley-VCH Verlag",
number = "12",

}

TY - JOUR

T1 - Human herpesvirus 6B immediate-early I protein contains functional HLA-A*02, HLA-A*03, and HLA-B*07 class I restricted CD8+ T-cell epitopes

AU - Iampietro, Mathieu

AU - Morissette, Guillaume

AU - Gravel, Annie

AU - Dubuc, Isabelle

AU - Rousseau, Matthieu

AU - Hasan, Aisha

AU - O'Reilly, Richard J.

AU - Flamand, Louis

PY - 2014

Y1 - 2014

N2 - Human herpesvirus 6B (HHV-6B) is a ubiquitous pathogen with frequent reactivation observed in immunocompromised patients such as BMtransplant (BMT) recipients. Adoptive immunotherapy is a promising therapeutic avenue for the treatment of opportunistic infections, including herpesviruses. While T-cell immunotherapy can successfully control CMV and EBV reactivations in BMT recipients, such therapy is not available for HHV-6 infections, in part due to a lack of identified protective CD8+ T-cell epitopes. Our goal was to identify CD8+ T-cell viral epitopes derived from the HHV-6B immediate-early protein I and presented by common human leukocyte Ag (HLA) class I alleles including HLA-A*02, HLA-A*03, and HLA-B*07. These epitopes were functionally tested for their ability to induce CD8+ T-cell expansion and kill HHV-6-infected autologous cells. Cross-reactivity of specific HHV-6B-expanded T cells against HHV-6A-infected cells was also confirmed for a conserved epitope presented by HLA-A*02 molecule. Our findings will help push forward the field of adoptive immunotherapy for the treatment and/or the prevention of HHV-6 reactivation in BMT recipients.

AB - Human herpesvirus 6B (HHV-6B) is a ubiquitous pathogen with frequent reactivation observed in immunocompromised patients such as BMtransplant (BMT) recipients. Adoptive immunotherapy is a promising therapeutic avenue for the treatment of opportunistic infections, including herpesviruses. While T-cell immunotherapy can successfully control CMV and EBV reactivations in BMT recipients, such therapy is not available for HHV-6 infections, in part due to a lack of identified protective CD8+ T-cell epitopes. Our goal was to identify CD8+ T-cell viral epitopes derived from the HHV-6B immediate-early protein I and presented by common human leukocyte Ag (HLA) class I alleles including HLA-A*02, HLA-A*03, and HLA-B*07. These epitopes were functionally tested for their ability to induce CD8+ T-cell expansion and kill HHV-6-infected autologous cells. Cross-reactivity of specific HHV-6B-expanded T cells against HHV-6A-infected cells was also confirmed for a conserved epitope presented by HLA-A*02 molecule. Our findings will help push forward the field of adoptive immunotherapy for the treatment and/or the prevention of HHV-6 reactivation in BMT recipients.

KW - CD8 T cells

KW - HHV-6

KW - Immediate-early 1 protein

KW - Immunotherapy

KW - Infectious disease

KW - Virology

UR - http://www.scopus.com/inward/record.url?scp=84908367477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908367477&partnerID=8YFLogxK

U2 - 10.1002/eji.201444931

DO - 10.1002/eji.201444931

M3 - Article

C2 - 25243920

AN - SCOPUS:84908367477

VL - 44

SP - 3573

EP - 3584

JO - European Journal of Immunology

JF - European Journal of Immunology

SN - 0014-2980

IS - 12

ER -